rs35396088

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2

The NM_006939.4(SOS2):​c.816T>C​(p.Ser272Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0233 in 1,613,700 control chromosomes in the GnomAD database, including 645 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.020 ( 75 hom., cov: 32)
Exomes 𝑓: 0.024 ( 570 hom. )

Consequence

SOS2
NM_006939.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:10

Conservation

PhyloP100: 0.199

Publications

6 publications found
Variant links:
Genes affected
SOS2 (HGNC:11188): (SOS Ras/Rho guanine nucleotide exchange factor 2) This gene encodes a regulatory protein that is involved in the positive regulation of ras proteins. Mutations in this gene are associated with Noonan Syndrome-9. [provided by RefSeq, Jul 2016]
SOS2 Gene-Disease associations (from GenCC):
  • Noonan syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
  • Noonan syndrome 9
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics, PanelApp Australia, G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.43).
BP6
Variant 14-50182505-A-G is Benign according to our data. Variant chr14-50182505-A-G is described in ClinVar as Benign. ClinVar VariationId is 475762.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.199 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0205 (3120/152334) while in subpopulation NFE AF = 0.0258 (1756/68026). AF 95% confidence interval is 0.0248. There are 75 homozygotes in GnomAd4. There are 1732 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 3120 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SOS2NM_006939.4 linkc.816T>C p.Ser272Ser synonymous_variant Exon 6 of 23 ENST00000216373.10 NP_008870.2 Q07890-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SOS2ENST00000216373.10 linkc.816T>C p.Ser272Ser synonymous_variant Exon 6 of 23 1 NM_006939.4 ENSP00000216373.5 Q07890-1
SOS2ENST00000543680.5 linkc.816T>C p.Ser272Ser synonymous_variant Exon 6 of 22 1 ENSP00000445328.1 Q07890-2
SOS2ENST00000556469.5 linkn.583T>C non_coding_transcript_exon_variant Exon 5 of 5 3

Frequencies

GnomAD3 genomes
AF:
0.0205
AC:
3120
AN:
152216
Hom.:
75
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00391
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00851
Gnomad ASJ
AF:
0.0138
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00165
Gnomad FIN
AF:
0.0927
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0258
Gnomad OTH
AF:
0.0143
GnomAD2 exomes
AF:
0.0220
AC:
5525
AN:
251286
AF XY:
0.0220
show subpopulations
Gnomad AFR exome
AF:
0.00375
Gnomad AMR exome
AF:
0.00564
Gnomad ASJ exome
AF:
0.0131
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0906
Gnomad NFE exome
AF:
0.0264
Gnomad OTH exome
AF:
0.0186
GnomAD4 exome
AF:
0.0236
AC:
34544
AN:
1461366
Hom.:
570
Cov.:
30
AF XY:
0.0231
AC XY:
16822
AN XY:
726998
show subpopulations
African (AFR)
AF:
0.00341
AC:
114
AN:
33480
American (AMR)
AF:
0.00588
AC:
263
AN:
44720
Ashkenazi Jewish (ASJ)
AF:
0.0136
AC:
355
AN:
26134
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39686
South Asian (SAS)
AF:
0.00208
AC:
179
AN:
86254
European-Finnish (FIN)
AF:
0.0883
AC:
4712
AN:
53380
Middle Eastern (MID)
AF:
0.00277
AC:
16
AN:
5768
European-Non Finnish (NFE)
AF:
0.0250
AC:
27769
AN:
1111564
Other (OTH)
AF:
0.0188
AC:
1136
AN:
60380
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.470
Heterozygous variant carriers
0
1531
3061
4592
6122
7653
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1036
2072
3108
4144
5180
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0205
AC:
3120
AN:
152334
Hom.:
75
Cov.:
32
AF XY:
0.0232
AC XY:
1732
AN XY:
74500
show subpopulations
African (AFR)
AF:
0.00390
AC:
162
AN:
41584
American (AMR)
AF:
0.00850
AC:
130
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
0.0138
AC:
48
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5192
South Asian (SAS)
AF:
0.00166
AC:
8
AN:
4832
European-Finnish (FIN)
AF:
0.0927
AC:
984
AN:
10610
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.0258
AC:
1756
AN:
68026
Other (OTH)
AF:
0.0142
AC:
30
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
145
291
436
582
727
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
40
80
120
160
200
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0216
Hom.:
22
Bravo
AF:
0.0133
Asia WGS
AF:
0.00173
AC:
6
AN:
3478
EpiCase
AF:
0.0191
EpiControl
AF:
0.0210

ClinVar

Significance: Benign
Submissions summary: Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:4
-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Dec 27, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

p.Ser272Ser in exon 6 of SOS2: This variant is not expected to have clinical significance because it does not alter an amino acid residue, is not located within the splice consensus sequence, and has been identified in 8.61% (568/6600) of Finnish chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs35396088). -

Mar 01, 2017
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Noonan syndrome 9 Benign:2
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Apr 12, 2017
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The SOS2 c.816T>C (p.Ser272Ser) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a polymorphism outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 2546/121094 control chromosomes at a frequency of 0.021025, which is approximately 8410 times the estimated maximal expected allele frequency of a pathogenic SOS2 variant (0.0000025), suggesting this variant is likely a benign polymorphism. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories; nor evaluated for functional impact by in vivo/vitro studies. Taken together, this variant is classified as benign. -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Cardiovascular phenotype Benign:1
May 17, 2019
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Noonan syndrome and Noonan-related syndrome Benign:1
Jun 03, 2021
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.43
CADD
Benign
7.2
DANN
Benign
0.79
PhyloP100
0.20
Mutation Taster
=67/33
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs35396088; hg19: chr14-50649223; API